Live Breaking News & Updates on Scan database

Stay informed with the latest breaking news from Scan database on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Scan database and stay connected to the pulse of your community

NSAIDs vs bDMARDs: Sex Disparities in Treatment Initiation for Axial Spondyloarthritis

New research examining treatment initiation patterns among patients with axial spondyloarthritis revealed significant sex-based disparities, shedding light on the process from diagnosis to therapeutic intervention.

Ibm , Arthritis-care-research , Arthritis-care , Scan-database , Sex-disparities , Bdmards , Nsaids , Rheumatology ,

Diabetes Dialogue: Latest Updates on Diabetes Management in Pregnancy

In this episode, hosts breakdown as pair of recent studies examining management of diabetes during pregnancy.

Israel , Israeli , Natalie-bellini , Diana-isaacs , Provention-bio , Eli-lilly , International-pregnancy-safety-study-inpress-consortium , Training-in-diabetes-technology , Israeli-maccabi-health-services , Drug-administration , Medtronic , Metabolic-care-center

GLP-1s, Antidiabetic Medications Show Safety in Pregnancy

New research shows use of the drugs in pregnancy is on the rise, particularly in the United States, and although teratogenic risks appear low, limitations are notable.

Denver , Colorado , United-states , Israel , Massachusetts , Boston , Sonia-hern , Linda-barbour , Harvard-chan-school , Israeli-maccabi-health-services , Endocrine-society , University-of-colorado-school-medicine

Use of Noninsulin Antidiabetic Meds Increasing for T2D in Pregnancy

Use of noninsulin meds not linked to significantly increased risk for major congenital malformations.

Israel , United-states , Stockholm , Sweden , Karolinska-institute , Israeli-maccabi-health-services , Healthday-news , Scan-database ,

Odds of opioid use in autoimmune rheumatic disease decreased 15% annually after 2014

Odds of opioid use in autoimmune rheumatic disease decreased 15% annually after 2014
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Titilola-falasinnu , Shenaz-bagha , Byrob-volansky , Ibm , Stanford-school-of-medicine , Stanford-school , Scan-database ,

Early Biologic Initiation for Crohn Disease Reduces Overall Health Care Costs

Patients with Crohn disease who start biologic treatment earlier use fewer health care resources.

Merativelp-marketscan , Digestive-diseases , Scan-database ,

Metformin Shows Potential to Prevent Macular Degeneration

People prescribed the diabetes drug metformin may be less likely to develop age-related macular degeneration.

Illinois , United-states , Worcester , Massachusetts , University-of-chicago , American , Dimitra-skondra , Ibm , Illinois-society-for-the-prevention-of-blindness , University-of-chicago-center , Institute-of-translational-medicine , Allergan

Exploring Relationship Between Oral Isotretinoin Use and Psychiatric Symptoms

Although oral isotretinoin is an effective treatment for acne, its potential association with psychiatric symptoms has limited its widespread clinical use.

United-states , American , Ibm , Journal-of-the-american-academy-dermatology , American-academy , Scan-database , ஒன்றுபட்டது-மாநிலங்களில் , அமெரிக்கன் , ஐபீயெம் , இதழ்-ஆஃப்-தி-அமெரிக்கன்-கலைக்கழகம்-தோல் நோய் , அமெரிக்கன்-கலைக்கழகம்

Taltz® Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis

Share this article
Share this article
INDIANAPOLIS, April 23, 2021 /PRNewswire/ -- Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company's (NYSE: LLY) Taltz
® (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderate to severe plaque psoriasis. In the first one-year network meta-analysis based on area under the curve, Taltz showed numerically greater cumulative benefits on completely clear skin over one year compared to seven other biologics, as measured by Psoriasis Area Severity Index (PASI) 100. In three real-world analyses of U.S. claims data ranging from one to three years, patients treated with Taltz stayed on treatment longer, were more adherent to the prescription and had more days on monotherapy compared to the other biologics studied. These results are being presented virtually at the American Academy of Dermatology's Virtual Meeting Experience (AAD VMX), April 23-25, 2021.

United-states , Oregon , American , Kevin-hern , Markg-lebwohl , Marlo-scott , Andrew-blauvelt , Eli-lilly , Exchange-commission , American-academy-of-dermatology-virtual-meeting-experience , Oregon-medical-research-center , Icahn-school-of-medicine-at-mount-sinai